Pfizer inSPIREd By Late-Stage PCSK9 Data
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Pfizer Dashes Hopes For A PCSK9 Pill
Pfizer has decided not to move forward with an oral PCSK9 blocker in early clinical development because the efficacy wouldn’t stand up to injectable rivals.
Repatha Monthly Dose Approved With On-Body Pushtronex System
Amgen’s PCSK9 blocker was cleared by FDA at a 420mg dose that can be administered once monthly via a hands-free device, offering a point of differentiation versus Sanofi/Regeneron’s Praluent.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.